Secondary analysis of VOYAGER-PAD (6564 patients with PAD after lower limb revascularisation): rivaroxaban plus aspirin vs placebo reduced the primary end point more with prior revascularisation (HR 0.73) than without (HR 0.94); bleeding rise was consistent.
Secondary analysisn = 6,564
Canonico et al. Low-Dose Rivaroxaban Plus Aspirin in Patients With PAD Undergoing Lower Extremity Revascularization With and Without History of Prior Limb Revascularization: Insight From the VOYAGER-PAD Trial